2-(4-bromophenyl)-3, 4-dimethoxy-4-methylbutenolide(25)
Yield 50.2 % as a white solid; m.p.251.9-253.3°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.53 (d, J = 8.1 Hz, 2H), δ 7.49 (d, J = 8.1 Hz, 2H), 3.97 (s, 3H), 3.33 (s, 3H), 1.77 (s, 3H). 13 C NMR (100 MHz, CDCl 3 ) δ 170. 21, 169.07, 131.43, 131.06, 127.79, 122.55, 104.62, 103.19, 59.85, 51.09, 22.88 
3, 4-dimethoxy-4-methyl-2-(p-tolyl) butenolide(26)
Yield 52.4 % as a white solid; m.p.212.6-213.1°C; 1 H NMR (400 MHz, DMSO) δ 7.42 (d, J = 8.1 Hz, 2H), 7.22 (d, J = 8.1 Hz, 2H), 3.86 (s, 3H), 3.23 (s, 3H), 2.33 (s, 3H), 1.69 (s, 3H). 13 C NMR (100 MHz, DMSO) δ 169. 30, 168.97, 137.45, 129.62, 128.52, 125.97, 104.62, 102.86, 59.97, 50.48, 22.61, 20.79 97, 169.19, 159.56, 131.03, 120.97,113.72, 105.46, 103.19, 59.83, 55.30, 50.97, 22.86 Compound 9 (7.73mmol) was dissolved in DMF (5 mL) and CH 2 Cl 2 (5 mL) at 0°C. 1.18 g（6.44 mmol) Oxalyl chloride was added dropwise to the reaction system, and then the mixture was stirred for 7 h at room temperature. After the reaction completed, the system was alkalized to neutral via NaHCO 3 solution, and the reaction system was partitioned between ethyl acetate (20 mL) and water (20 mL). The organic phase was dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to yield 95% of compound 31 as a red solid.
Synthesis Procedure for 2-(4-methoxyphenyl)-3-morpholinobutenolide (32)
Compound 31 was dissolved in THF (2 mL), and K 2 CO 3 (778 mg, 5.64 mmol) was added to the solution at room temperature. Then 492 mg (5.64 mmol) morpholine was added dropwise to reaction system, and the mixture was stirred for 3h. Then volatiles were removed under reduced pressure, and the residue was partitioned between ethyl acetate (20 mL) and water (20 mL). The organic phase was dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography to yield 32 as a white solid. To a solution of 32 (1.52 mmol) in CH 3 OH (2 mL) was added (CH 2 O) n (27.3 mg, 0.91 mmol ) and CH 3 ONa (24.6 mg, 0.45 mmol). The mixture system was heated at about 75°C. Then (CH 2 O) n (13.6 mg, 0.45 mmol ) and CH 3 ONa (24.6 mg, 0.45 mmol) were added into the reaction after 8 hours. The reaction was monitored by TLC. After the reaction completed, then volatiles were removed under reduced pressure, and the residue was partitioned between ethyl acetate (3*15 ml) and water (20 ml). The organic phase was dried over anhydrous Na 2 SO 4 , and the solvent was removed. 159.08,159.04, 131.58, 123.98, 113.78, 103.56, 99.24, 66.75, 55.29, 50.83, 48.26,29.83, 24.93 07, 159.76, 133.55, 131.73, 130.42, 128.47,128.42, 103.62, 98.10, 66.65, 50.92, 48.47,40.98 74, 159.04, 137.47, 130.30, 128.98, 128.83, 103.56, 99.23, 66.75, 50.83, 48.26, 24.93,21.23 
3-(4-chlorophenyl)-5-((4-chlorophenyl)(hydroxy)methyl)-4-methoxy-4-methylbutenolide(45)
To solution of compound 44 (300 mg, 0.9 mmol) in CH 3 OH (2 mL) was added CH 3 ONa (58.84 mg, 1.01 mmol) and 4-chlorobenzaldehyde (136.5 mg, 1.1 mmol) at 0°C. The resulting mixture was stirred at 0°C for 30 min, then warmed to room temperature for 4 h. After workup, chromatography with EA in PE gave compound 45 as a white solid(45.4 %). 1 40, 136.94, 134.72, 132.26, 131.40, 129.25, 128.67, 122.67, 118.34, 84.61,76.86, 61.50, 61.11, 30.91, 20.43 
-(4-chlorophenyl)-4-(hydroxy(p-tolyl)methyl)-3-methoxy-4-methylbutenolide(46)
Compound 461 as a white solid was prepared with yield of 48.6 % from compound 44 (800 mg, 3.35 mmol) and p-tolualdehyde (370.6 mg, 4.02 mmol) by the same procedure as described for compound 45. 1 H NMR (400 MHz, CDCl 3 ) δ 7.53 (d, J=8.5 Hz, 2H), 7.43 (d, J=8.5 Hz, 2H), 7.38-7.35(m, 2H), 7.10 (t, J=8.6 Hz, 2H), 5.63 (s, 1H), 3.80 (s, 3H), 2.71 (s, 3H), 1.35 (s, 3H) 13 C NMR (100 MHz, CDCl 3 ) δ 173. 32, 171.69, 161.53, 136.32, 132.62, 132.53, 131.50, 130.41, 129.23, 125.17 (d, J=3.6 Hz), 115.49, 115.28, 104.00, 83.48, 81.39, 61.25, 39.57, 20.14 60, 175.07, 171.98, 171.42, 156.49, 156.29, 154.04, 153.84, 140.30, 140.22, 140.18, 140.09, 134.51, 134.43, 133.01, 132.94, 132.85, 132.78, 132.00, 131.71, 128.41, 128.31, 128.24, 128.82, 125.00, 124.25, 124.22, 122.74, 122.71, 118.84, 118.27, 115.84, 115.62, 115.00, 114.78, 103.52, 103.37, 85.11, 84.81, 75.61, 66.91, 61.09, 60.79, 50.82, 50.79, 50.76, 50.72, 20.50, 19.81 Figure S1 . 1 Figure S2 . 13 Figure S3 . 1 Figure S4 . 13 Figure S5 . 1 Figure S6 . 13 Figure S7 . 1 Figure S8 . 13 Figure S9 . 1 Figure S10 . 13 Figure S11 . 1 Figure S12 . 13 Figure S13 . 1 Figure S14 . 13 Figure S15 . 1 Figure S16 . 13 Figure S17 . 1 Figure S18 . 13 Figure S30 . 13 Figure S32 . 13 Figure S34 . 13 Figure S35 . 1 Figure S36 . 13 Figure S42 . butenolide(59) S27 Figure S43 . 1 Figure S44 . 13 
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S21 Figure S31. 1 H NMR of 2-(4-chlorophenyl)-4-(hydroxy(p-tolyl)methyl)-3-methoxy-4-methylbutenolide (46)
C NMR of 2-(4-chlorophenyl)-4-(hydroxy(p-tolyl)methyl)-3-methoxy-4-methylbutenolide (46)
S22 Figure S33. 1 H NMR of 2-(4-chlorophenyl)-4-(hydroxy(pyridin-2-yl)methyl)-3-methoxy-4-methylbutenolide (47)
C NMR of 2-(4-chlorophenyl)-4-(hydroxy(pyridin-2-yl)methyl)-3-methoxy-4-methylbutenolide (47)
S23
H NMR of 2-(4-chlorophenyl)-4-(hydroxy(4-morpholinophenyl)methyl)-3 -methoxy-4 -methylbutenolide (48)
C NMR of 2-(4-chlorophenyl)-4-(hydroxy(4-morpholinophenyl)methyl)-3-methoxy-4 -methylbutenolide
H NMRof 4-methoxy-4-methyl-3-morpholino-3-(p-tolyl)butenolide(59)
H NMR of 2-(3-fluorophenyl)-4-methoxy-4-methyl-3-morpholinobutenolide(60)
C NMR of 2-(3-fluorophenyl)-4-methoxy-4-methyl-3-morpholinobutenolide(60)
S28 3.Biology methods for anti influenza H1N1 activity in vitro and in vivo.
Virus
Influenza A virus (H1N1) was used for challenge infections, it was purchased from China Center for Type Culture Collection. Viral stocks were produced in Madin-Darby canine kidney (MDCK).
Cell Lines
MDCK used in this study was purchased from ATCC. It was maintained in Dulbecco ' s modified Eagle ' s medium (DMEM ； Hyclone, USA) supplemented with 10% Fetal bovine serum (GBICO,USA) and 1% penicillin/streptomycin (Solarbio, Beijing, China).
Virus propagation
Viral stocks were produced in Madin-Darby canine kidney (MDCK) cells. 90% confluent cells were infected with the virus in 10mL medium of a moi of 0.01 and incubated for five days until an overall cytopathic effect (CPE) could be observed. Virus containing cell culture supernatants were collected and frozen in aliquots from -20 to -80 °C. The results of all TCID 50 assays were calculated according to the Reed and Muench method.
Cytotoxicity assay
An MTT assay was performed to evaluate the cytotoxic effects of all compounds on MDCK cells. Cell monolayers were washed after the 24h cultivation and a series of concentrations of compounds (0~800 μM) was added to the cells. After incubation at 37°C in a CO 2 incubator for 72h, 20μL MTT was added to each well and the plates were further incubated for 3h.
Solubilisation of the formazan crystals formed during this period was achieved by the addition of dimethyl sulfoxide (DMSO). The absorbance (OD) at 490 nm was measured using a microplate reader. Cell survival rate was expressed as the percentage of compounds treated average OD value / control average OD value.
Antiviral activity assay
MDCK cells were placed in 24-well cell culture plates. After 24h, washing with PBS for three times, cells were incubated with H1N1 in DMEM medium for 2h in 0.01 moi. Then different concentrations of all compounds ranging from 5 to 100 μM was added to cells. RI (100μM) and Ose (3μM) were used as positive control. All cultures were incubated at 37°C for 72 h. Inhibition rate (%) = [(the average OD value of drug-treatment -the average OD value of virus controls)/(the average OD value of cell controls -the average OD value of virus controls)] × 100%.
NA inhibition assay
The influenza A virus have two types of glycoprotein of hemagglutinin (HA) and neuraminidase (NA). A fluorescence-based NA inhibition assay was used to determine whether the compounds have the abilities to suppress NA protein. Mice were randomly kept in groups of 4 (n=8). There were normal control group, the group of viruses, high dose group of compound compound 37 (200mg/kg/d), low-dose group of Compound compound 37 (50mg/kg/d). After seven days feeding, the other group were inoculated by the intranasal route with 50μL of H1N1 with a titer of 1×10 -4.5 influenza virus apart from the control group. The compounds were administered according to body weight by oral gavage once daily for 7 days after 2 hours of virus infection. Mice were sacrificed to calculate lung index and so on after day 5 post-infection.
Clinical follow-up and sampling
During the experiment, mice were clinically monitored daily for the development of clinical signs including fever, fatigue, anorexia, dyspnea and cough. Body weights and body temperature were recorded daily. Removal of the eye of mice and the blood were kept in heparinized tubes and processed into serum after the last administration. Lungs were taken and weighed, a part of lung tissue were prepared for histological analysis. The rest of lung tissue was stored at -80 °C for further use.
Gross pathology and Histopathology
At necropsy, the lungs immediately examined macroscopically and photographs taken for further analysis. A small sections of lung were fixed in 10% buffered formalin for histopathology.
Fix tissues were dehydrated, embedded in paraffin and 5μM sections were cut for histological examination. Lung sections from the portion most consistently affected by gross lesions (well-demarcated purple dark red areas of tissue consolidation) were stained using a hematoxylin/eosin (HE) standard staining protocol and examined microscopically (this study was done by PhD Yan of school of basic medical sciences of Zhengzhou university).
Quantitative real-time RT-PCR (qRT-PCR)
The total RNA was extracted from lung tissue using the RNA prepare Tissue Kit (TIANGEN, Beijing, China) according to the manufacturer's instructions. The concentration of RNA was detected by NANODROP 2000 (Thermo, USA) and the integrity of RNA was detected trough agarose gel electrophoresis. Then RNA was subjected to reverse transcription using the Thermo Scientific RevertAid First Strand cDNA Synthesis Kit (Thermo, Beijing, China). The reaction setup was incubated for 60 min at 42°C and then 5 min at 70°C. Quantification of IV gene copy numbers was performed using a pan-Influenza A-M1.2 assay by qRT-PCR for with an appropriate in vitro transcribed RNA standard. The primers are listed below.
Front primer: AGATGAGTCTTCTAACCGAGGTCG Reserve primer: TGCAAAAACATCTTCAAGTCTCTG
